Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CJU
|
|||
| Former ID |
DIB009218
|
|||
| Drug Name |
DLX-105
|
|||
| Synonyms |
DLX-106; ESBA-105 (intra-articular formulation), ESBATech; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), Delenex; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), ESBATech
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Osteoarthritis [ICD-11: FA00-FA05; ICD-9: 715] | Phase 2 | [1] | |
| Company |
ESBATech AG
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01624376) Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease. U.S. National Institutes of Health. | |||
| REF 2 | Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol Pharmacol. 2003 Mar;63(3):690-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.